ConductScience.org, home

Comparison · NCT04462536-c5ec02eb

Nerinetide vs Placebo: Mortality Rate, as Defined by Event Rate (Percent) for Mortality Over the 90-day Study Period.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nerinetide vs Placebo: Mortality Rate, as Defined by Event Rate (Percent) for Mortality Over the 90-day Study Period. Trial comparisons, record NCT04462536-c5ec02eb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04462536-c5ec02eb

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1920.1580.23wilson
Risk in group 20.1770.1420.217wilson
Risk difference, group 1 minus group 20.0149-0.03780.0667newcombe hybrid score
Risk ratio, group 1 over group 21.080.8161.44log
Odds ratio, group 1 over group 21.10.7791.56log
Number needed to treat, for one more participant with the outcome on Nerinetide than on Placebo67.3from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Nerinetide
Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes~Nerinetide: Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
87454OG001
Group 2PlaceboVehicle only~Placebo: Vehicle only70396OG000

Outcome

Type
SECONDARY
Title
Mortality Rate, as Defined by Event Rate (Percent) for Mortality Over the 90-day Study Period.
Description
The estimand of mortality rate was the adjusted unconditional population difference in the number of deaths observed divided by the number of participants observed over the 90-day study period (mortality proportions) between treatment conditions (nerinetide vs. placebo) in the target patient population at Day 90. Deaths occurring over the Day 90 period were considered as non-responses.
Time frame
90 days
Population
ITT Population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
NCT number
NCT04462536
Phases
PHASE3
Conditions
Stroke, Acute
Interventions
Placebo, Nerinetide
Lead sponsor
NoNO Inc.
Results first posted
2025-06-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04462536-c5ec02eb